Cell and gene therapy

The cell and gene market is thriving with innovation, investment, partnerships, and M&A activity. But much remains unclear about how these therapies can deliver full value, and where pharma and biotech leaders should invest energy and resources to get these transformational therapies in patients’ hands.

Working together

We partner with cell and gene therapy manufacturers, technology providers, pharma, and biotechs to determine the most effective strategies for maximising the potential of these groundbreaking treatments.

Working at the intersection of technology, science, innovation, strategy, and healthcare, we understand the factors influencing value delivery and are here to help you navigate the complexity of evolving regulatory frameworks and rapid scientific advancements.

Together, we will realise the promise of cell and gene therapies and create lasting impact that transforms the future of medicine and patient care.

Talk to us about

Digital transformation

Enhancing the power of CGT science by building advanced analytics, digital workflow automation and patient facing digital services

Equipment and consumable development

Supporting therapy manufacturers with the improvement of their CGT manufacturing processes, from technology selection to supply chain, demand and capacity modelling to facility strategy

Sustainability

Designing for sustainability and circularity, and supporting industries in their material and waste strategies.

Technology strategy and market insights

For existing and new players in the CGT space to understand, assess and leverage new technologies and technology partners to grow in the CGT market.

Get in touch

Featured insight

Medical researcher working in laboratory

Report

Five key manufacturing challenges in autologous commercial cell and gene therapies

How to address the complex manufacturing challenges arising from autologous therapies’ personalized nature.

Business people brainstorming at whiteboard in office

In the media

Key considerations for Cell & Gene Therapy developers to tap into AI

A look at outsourcing vs. developing in-house solutions, data acquisition strategies, the three stages of managing AI/ML algorithms, and more.

Video

How Things Work: Cell and gene therapy

Cell and gene therapies are a new class of treatments that can teach our bodies how to fight specific diseases or restore lost functions. They’re exciting because they have potential to beat life-challenging conditions.

In the media

The RNA Therapeutics Race: How can pharma stay ahead of the wave?

It is crucial for pharmaceutical companies to strategically position themselves within the RNA sector.

Expert views

Focus is usually key in bringing new products and services to market in highly innovative sectors. However, to mitigate risk in a highly uncertain market, established pharma and biotech companies developing biotherapeutics should look at diversifying their portfolio through the development and/or acquisition of multiple CGT platforms across different therapeutic areas.”

Paolo Siciliano Cell and gene therapy

Read the article

We believe scaling manufacturing, improving market access, patient centricity and leveraging innovative technologies for the pre-clinical and clinical settings are the four key areas to improving accessibility to CGTs.”

Anu Solanki Technology

Read the article

To support the successful delivery of an increasing number of therapies to patients, it is critical to leverage digital tools and experiences across development phases and among the various stakeholders.”

Gloria Lam Cell and gene therapy

Read the insight

To accelerate development and production of CAR-T, pharma companies may need to put in place patent cross-licensing deals, as is the case in the electronics and telecom industries. This will require companies to develop strategic patent portfolios to ensure they have the right size, geographical spread and quality to achieve success at the negotiation table.”

Byoung Min Life sciences

Read the insight